Literature DB >> 20060033

Histone deacetylase inhibition enhances adenoviral vector transduction in inner ear tissue.

A Taura1, K Taura, Y H Choung, M Masuda, K Pak, E Chavez, A F Ryan.   

Abstract

Adenovirus vectors (AdVs) are efficient tools for gene therapy in many tissues. Several studies have demonstrated successful transgene transduction with AdVs in the inner ear of rodents [Kawamoto K, Ishimoto SI, Minoda R, Brough DE, Raphael Y (2003) J Neurosci 23:4395-4400]. However, toxicity of AdVs [Morral N, O'Neal WK, Rice K, Leland MM, Piedra PA, Aguilar-Cordova E, Carey KD, Beaudet AL, Langston C (2002) Hum Gene Ther 13:143-154.] or lack of tropism to important cell types such as hair cells [Shou J, Zheng JL, Gao WQ (2003) Mol Cell Neurosci 23:169-179] appears to limit their experimental and potential clinical utility. Histone deacetylase inhibitors (HDIs) are known to enhance AdV-mediated transgene expression in various organs [Dion LD, Goldsmith KT, Tang DC, Engler JA, Yoshida M, Garver RI Jr (1997) Virology 231:201-209], but their effects in the inner ear have not been documented. We investigated the ability of one HDI, trichostatin A (TSA), to enhance AdV-mediated transgene expression in inner ear tissue. We cultured neonatal rat macular and cochlear explants, and transduced them with an AdV encoding green fluorescent protein (Ad-GFP) under the control of a constitutive promoter for 24 h. In the absence of TSA, GFP expression was limited, and very few hair cells were transduced. TSA did not enhance transduction when applied at the onset of Ad-GFP transduction. However, administration of TSA during or just after Ad-GFP application increased GFP expression in supporting cells approximately fourfold. Moreover, vestibular hair cell transduction was enhanced approximately sixfold, and that of inner hair cells by more than 17-fold. These results suggest that TSA increases AdV-mediated transgene expression in the inner ear, including the successful transduction of hair cells. HDIs, some of which are currently under clinical trials (Sandor et al., 2002), could be useful tools in overcoming current limitations of gene therapy in the inner ear using Ad-GFP. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20060033      PMCID: PMC2856459          DOI: 10.1016/j.neuroscience.2009.12.064

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  36 in total

1.  Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase.

Authors:  T Yamano; K Ura; R Morishita; H Nakajima; M Monden; Y Kaneda
Journal:  Mol Ther       Date:  2000-06       Impact factor: 11.454

2.  Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.

Authors:  M Kitazono; M E Goldsmith; T Aikou; S Bates; T Fojo
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

Review 3.  Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails.

Authors:  Y Zhang; D Reinberg
Journal:  Genes Dev       Date:  2001-09-15       Impact factor: 11.361

4.  Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.

Authors:  M Kitazono; Y Chuman; T Aikou; T Fojo
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

5.  Cochlear gene delivery through an intact round window membrane in mouse.

Authors:  J Jero; A N Mhatre; C J Tseng; R E Stern; D E Coling; J A Goldstein; K Hong; W W Zheng; A T Hoque; A K Lalwani
Journal:  Hum Gene Ther       Date:  2001-03-20       Impact factor: 5.695

6.  A modified adenovirus can transfect cochlear hair cells in vivo without compromising cochlear function.

Authors:  A E Luebke; J D Steiger; B L Hodges; A Amalfitano
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

7.  Transcriptionally active drugs improve adenovirus vector performance in vitro and in vivo.

Authors:  C Gaetano; A Catalano; R Palumbo; B Illi; G Orlando; G Ventoruzzo; F Serino; M C Capogrossi
Journal:  Gene Ther       Date:  2000-10       Impact factor: 5.250

8.  In vivo adenoviral transduction of the neonatal rat cochlea and middle ear.

Authors:  S Dazert; C Aletsee; D Brors; C Gravel; M Sendtner; A Ryan
Journal:  Hear Res       Date:  2001-01       Impact factor: 3.208

9.  Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons.

Authors:  Núria Morral; Wanda K O'Neal; Karen Rice; M Michelle Leland; Pedro A Piedra; Estuardo Aguilar-Córdova; K Dee Carey; Arthur L Beaudet; Claire Langston
Journal:  Hum Gene Ther       Date:  2002-01-01       Impact factor: 5.695

10.  Aminoglycoside-induced histone deacetylation and hair cell death in the mouse cochlea.

Authors:  Fu-Quan Chen; Jochen Schacht; Su-Hua Sha
Journal:  J Neurochem       Date:  2009-01-29       Impact factor: 5.372

View more
  2 in total

Review 1.  Cellular targeting for cochlear gene therapy.

Authors:  Allen F Ryan; Lina M Mullen; Joni K Doherty
Journal:  Adv Otorhinolaryngol       Date:  2009-06-02

2.  Adeno-associated virus-mediated gene delivery into the scala media of the normal and deafened adult mouse ear.

Authors:  L A Kilpatrick; Q Li; J Yang; J C Goddard; D M Fekete; H Lang
Journal:  Gene Ther       Date:  2011-01-06       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.